C
Corrado Caracò
Researcher at National Institutes of Health
Publications - 134
Citations - 3844
Corrado Caracò is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Melanoma & Sentinel lymph node. The author has an hindex of 31, co-authored 115 publications receiving 3333 citations.
Papers
More filters
Journal ArticleDOI
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Maria Colombino,Mariaelena Capone,Amelia Lissia,Antonio Cossu,Corrado Rubino,Vincenzo De Giorgi,Daniela Massi,Ester Fonsatti,Stefania Staibano,Oscar Nappi,Elena Pagani,Milena Casula,Antonella Manca,MariaCristina Sini,Renato Franco,Gerardo Botti,Corrado Caracò,Nicola Mozzillo,Paolo A. Ascierto,Giuseppe Palmieri +19 more
TL;DR: The findings about the prevalence of BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be useful in the management of this disease.
Journal ArticleDOI
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Antonio M. Grimaldi,Ester Simeone,Diana Giannarelli,Paolo Muto,Sara Falivene,Valentina Borzillo,Francesca Maria Giugliano,Fabio Sandomenico,Antonella Petrillo,Marcello Curvietto,Assunta Esposito,Miriam Paone,Marco Palla,Giuseppe Palmieri,Corrado Caracò,Gennaro Ciliberto,Nicola Mozzillo,Paolo A. Ascierto +17 more
TL;DR: RT after ipilimumab may lead to abscopal responses in some patients with advanced melanoma correlating with prolonged OS, and it is suggested that local responses to RT may be predictive of abscopy responses.
Journal ArticleDOI
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone,Diana Giannarelli,Domenico Mallardo,Gabriele Madonna,Lucia Festino,Antonio M. Grimaldi,Vito Vanella,Ester Simeone,Miriam Paone,Giuseppe Palmieri,Ernesta Cavalcanti,Corrado Caracò,Paolo A. Ascierto +12 more
TL;DR: Both Neutrophil-to-lymphocyte ratio (NLR) and derived (d) NLR were associated with improved survival when baseline levels were lower than cut-off values, and NLR and dNLR are simple, inexpensive and readily available biomarkers that could be used to help predict response to immunotherapy in patients with advanced melanoma.
Journal ArticleDOI
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone,Giusy Gentilcore,Diana Giannarelli,Antonio M. Grimaldi,Corrado Caracò,Marcello Curvietto,Assunta Esposito,Miriam Paone,Marco Palla,Ernesta Cavalcanti,Fabio Sandomenico,Antonella Petrillo,Gerardo Botti,Franco Fulciniti,Giuseppe Palmieri,Paola Queirolo,Paolo Marchetti,Virginia Ferraresi,Gaetana Rinaldi,Maria Pia Pistillo,Gennaro Ciliberto,Nicola Mozzillo,Paolo A. Ascierto +22 more
TL;DR: Changes in some immunological markers between baseline and the fourth ipilimumab infusion appear to be associated with disease control and survival, but verification in prospective clinical trials is required.
Journal ArticleDOI
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.
Annette H. Chakera,Annette H. Chakera,Birger Hesse,Zeynep Burak,James R. Ballinger,Allan Britten,Corrado Caracò,Alistair J. Cochran,Martin G. Cook,Krzysztof T. Drzewiecki,Richard Essner,Einat Even-Sapir,Alexander M.M. Eggermont,Tanja Gmeiner Stopar,Christian Ingvar,Martin C. Mihm,Stanley W. McCarthy,Nicola Mozzillo,Omgo E. Nieweg,Richard A. Scolyer,Hans Starz,John F. Thompson,Gianluca Trifirò,Giuseppe Viale,Sergi Vidal-Sicart,Roger F. Uren,Wendy Waddington,Arturo Chiti,Alain Spatz,Alessandro Testori +29 more
TL;DR: The recommendations are designed to assist in the practice of referral to, performance, interpretation and reporting of all steps of the sentinel node procedure in the hope of setting state-of-the-art standards for good-quality evaluation of possible spread to the lymphatic system in intermediate-to-high risk melanoma without clinical signs of dissemination.